Second-line chemotherapy in advanced and metastatic CRC

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Roqué I Figuls, Marta ^a   Solà, Ivan ^a   Martin Richard, Marta ^a   López, Juan José ^a   Cosp, Xavier Bonfill ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SYSTEMATIC REVIEW;

EID: 70349088245     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006875.pub2     Document Type: Review

References (45)

1. Blijham G, Mesbah M, Glimelius B. Quality of life evaluation of cpt-11 compared to best supportive care or infusional 5-fu in patients with 5-fu resistant advanced colorectal cancer. 1998 ASCO Annual Meeting (abstract). 1998:ab 1592.
2. * Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. Semin Oncol 1999;26(1 Suppl 5):6-12.
3. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418 (Pubitemid 28510874)
4. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two Irinotecan dosing regimens in secondline therapy of metastatic colorectal cancer. J Clin Oncol, 2003;21 (5):807-814 (Pubitemid 46606439)
5. Lal KR, Norman R, Ross J, et al. Aphase III, randomized,multicentre, trial of irinotecan until disease progression (PD) versus 8 cycles, in advanced colorectal cancer (CRC) resistant to fluoropyrimidines. 22. Proc Am Soc Clin Oncol 2003;22:254 (ab 1017).
6. * Lal R, Dickson J, Cunningham D, et al.A randomised trial comparing defined-duration with continuous Irinotecan until disease progression in Fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 2004;22(15):3023-3031
7. Pitot HC, Rowland KM, Sargent DJ, et al.N9841: A randomised phase III equivalence trial of Irinotecan (CPT-11) versus Oxaliplatin/ 5-Fluorouracil (5FU)/Leucovorin (FOLFOX4) in patients with advanced colorectal cancer previously treated with 5FU. J Clin Oncol, 2005. ASCO Annual Meeting Proceedings. Vol 23, No. J Clin Oncol 2005 ASCO Annual Meeting Proceedings;23:16S (ab 3506).
8. * Rothenberg ML, Oza AM, Bigelow RH, et al.Superiority of Oxaliplatin and Fluorouracil-Leucovorin compared with either therapy alone in patients with progressive colorectal cancer after Irinotecan and Fluorouracil-Leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21(11):2059-2069
9. Rothenberg ML, Oza AM, Burger B, et al.Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin . 22. Proc Am Soc Clin Oncol 2003;22:525 (abstract 1011).
10. Levy-Piedbois C, Durand-Zaleski I, Juhel H, Schmitt C, Bellanger A, Piedbois P. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. Ann Oncol 2000;11(2):157-161 (Pubitemid 30148728)
11. * Rougier P, Van Cutsem E, Bajetta E, et al.Randomised trial of Irinotecan versus Fluorouracil by continuous infusion after Fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 1998;352(9138):1407-1412
12. Van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Seminars in Oncology 1999;26(1 Suppl 5):13-20. (Pubitemid 29174245)
13. Tsavaris N, Ziras N, Kosmas C, et al.Two different schedules of Irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-Fluorouracil and Leucovorin combination. A randomised study. Cancer Chemother Pharmacol, 2003;52(6):514-519 (Pubitemid 37491643)
14. Aravantinos G, Skarlos DV, Kosmidis P, Georgoulias V, Sgouros I, Bafaloukos D, et al.Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy. Crit Rev Oncol Hematol 1999;32(3):209-219
15. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, et al.Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91(8):1453-1458 (Pubitemid 39486347)
16. Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, et al.Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. Ann Oncol 2000;11(10):1323-1333 (Pubitemid 30832257)
17. Comella P, Crucitta E, De Vita F, De Lucia L, Farris A, Del Gaizo F, et al.Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 2002;13(6):866-873 (Pubitemid 34752681)
18. Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previously treated with 5-fluorouracil (5-Fu). Am J Clin Oncol 1983;6(2):175-180
19. Fisher MD. Irinotecan/5-FU/leucovorin, oxaliplatin/ 5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer. Clin Colorectal Cancer 2001;1(2):85-86
20. Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, et al.Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993;11 (2):330-335 (Pubitemid 23046825)
21. Mitry E, Ducreux M, Rougier P. [Second-line irinotecan chemotherapy in the treatment ofmetastatic colorectal cancers: phase III trials]. Bull Cancer 1998;Spec No:38-42.
22. Nagourney RA, Sommers BL, Harper SM, Radecki S, Evans SS. Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. Br J Cancer 2003;89(9):1789-1795 (Pubitemid 37464155)
23. Popov IP, Jelic SB, Matijasevic MM, Grbic B, Babic DR. Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC). J Exp Clin Cancer Res 2004;23(3):395-401. (Pubitemid 39490623)
24. Ramanathan RK, Clark JW, Kemeny NE, Lenz HJ, Gococo KO, Haller DG, et al.Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003;21(15):2904-2911
25. Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, et al.Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22(19):3950-3957 (Pubitemid 41079877)
26. Valone FH, Kohler M, Fisher K, Hannigan J, Flam M, Gandara D, et al.A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone. NCI Monogr 1987;5:175-177 (Pubitemid 18000416)
27. Aaronson NK, Ahmedzai S, Bergman B, et al.The European Organisation for Research and Treatment of Cancer QLQ-30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376 (Pubitemid 23073154)
28. Ahmed N, Ahmedzai SH, Vora V, Hillam S, Paz S. Supportive care for patients with gastrointestinal cancer. Cochrane Database of Systematic Reviews 2004, Issue 3. [MEDLINE: Art. No.: CD003445. DOI: 10.1002/14651858.; : CD003445][Art. No.: CD003445. DOI: 10.1002/14651858.CD003445.pub2]
29. Best P, Simmonds C, Baughan R, et al.Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2000, Issue 1. [Art. No.: CD001545. DOI: 10.1002/14651858.CD001545]
30. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc.html.
31. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. Journal of Clinical Oncology 2007;25(22):3224-3229 [MEDLINE: 17664470] (Pubitemid 47325605)
32. Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Section 8. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd, 2005.
33. Goldberg M. Therapy for Metastatic Colorectal Cancer. Oncologist 2006;11:981-987
34. Grothey A. Is there a third-line therapy for metastatic colorectal cancer?. Semin Oncol, 2006 Dec;33(6 Suppl 11):S36-8. (Pubitemid 44908571)
35. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook.org..
36. National Cancer Institute. Guidelines for the Reporting of Adverse Drug Reaction. Bethesda: Division of Cancer Center Treatment. Division of Cancer Center Treatment. National Cancer Institute, 1998.
37. Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review). http://www.nice.org.uk/TA093.pdf.
38. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834 (Pubitemid 28562978)
39. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31(1):150-153 [PUBMED: 11914311] (Pubitemid 34284917)
40. Saunders M, Ivanson T.Management of advanced colorectal cancer: state of the art. Br J Cancer 2006;95:131-138 (Pubitemid 44050911)
41. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993 Mar 20;306(6880):752-755 (Pubitemid 23080053)
42. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 Feb 2;92(3):205-216 (Pubitemid 30099779)
43. Wagner AD, Arnold D, Behl S, Fleig WE, Haerting J. Anti-angiogenic therapy for metastatic colorectal cancer.. Cochrane Database of Systematic Reviews 2005, Issue 2. [Art. No.: CD005392. DOI: 10.1002/14651858]
44. World Health Organization. Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization, 1979: 15-22.
45. World Health Organisation/International Agency for Research on Cancer. The World Cancer Report - the major findings. Cent Eur J Public Health 2003;11:177-9. * Indicates the major publication for the study